Quarterly report pursuant to sections 13 or 15(d)

Stock-Based Compensation (Tables)

v2.4.0.6
Stock-Based Compensation (Tables)
 9 Months Ended
Mar. 31, 2013
Share-Based Compensation [Abstract]  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

AntriaBio has computed the fair value of all options granted during the nine months ended March 31, 2013 using the following assumptions:

 

Expected volatility

 

 

111

%

Risk free interest rate

 

 

0.88

%

Expected term (years)

 

 

5

 

Dividend yield

 

 

0

%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
Stock option activity is as follows:
 
          Weighted     Weighted Average  
    Number of     Average     Remaining  
    Options     Exercise Price     Contractual Life  
Outstanding, June 30, 2012     -     $ -       -  
Granted     9,000,000     $ 0.75          
Outstanding, March 31, 2013     9,000,000     $ 0.75       4.8  
                         
Exercisable at March 31, 2013     5,097,223     $ 0.75       4.8
Schedule Of Warrants Issued To Agents Activity [Table Text Block]
AntriaBio issued warrants to agents in conjunction with the closing of its convertible notes payable as follows:
 
 
          Weighted     Weighted Average  
    Number of     Average     Remaining  
    Warrants     Exercise Price     Contractual Life  
Outstanding, June 30, 2012     -     $ -       -  
Warrants issued to placement agents     248,542     $ 0.33          
Warrants issued to placement agent     1,400,000     $ -          
Warrants issued to placement agent     110,000     $ 0.85          
Outstanding, March 31, 2013     1,758,542     $ 0.31       4.4
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]

Significant assumptions were as follows:

 

Expected volatility

 

 

111

%

Risk free interest rate

 

 

0.88

%

Expected term (years)

 

 

4.375-5

 

Dividend yield

 

 

0

%